Shandong Boan Biotechnology Company., Limited. Class H
HHKEX:69553.20
HKD
+0.11
(+3.39%)
Shandong Boan Biotechnology Company., Limited. Class H
HKEX:6955
(Hong Kong Exchange)
Recent
price
3.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Shandong Boan Biotechnology Co., Ltd. (Ticker: 6955.HK) engages in the development, manufacture, and commercialization of biopharmaceuticals with a focus on therapeutic antibodies across oncology, autoimmune diseases, ophthalmology, and metabolic diseases; it operates through three core technology platforms—Fully Human Antibody Transgenic Mouse with Phage Display, Bispecific T-cell Engager (BiTE) platforms, and Antibody-Drug Conjugate (ADC) technology—supporting domestic China operations and international markets. The company maintains a diversified portfolio of monoclonal antibodies and antibody-related therapeutics under multiple brands, including BioNew, BioBay, BioDia, and BA1104, targeting cancer types such as lung cancer, glioblastoma, ovarian cancer, and bone metastases, alongside developing novel modalities like long-acting GLP-1 receptor agonists and ophthalmic antibody fusion proteins; it pursues early, mid, and late-stage clinical development across its pipeline, with ongoing international phase I/III studies in Europe, the United States, Japan, and other regions. Headquarters are in Yantai, Shandong Province, China, with a primary listing on the Hong Kong Stock Exchange, and ongoing expansion of manufacturing, R&D capabilities, and global partnerships to scale commercialization and clinical development. The company reports strategic collaborations and partnerships to advance its bioscience platform, including licensing, co-development, and research collaborations, while executing regulatory submissions and approvals in multiple jurisdictions to enable broader global access to its antibody-based portfolio. Founding year is not publicly disclosed in this description, but the company positions itself as a China-based biopharmaceutical innovator with a comprehensive in-house discovery and development engine supported by its three technology platforms, aiming to transform treatment paradigms in selected oncology, autoimmune, ophthalmic, and metabolic indications. The firm’s geographic footprint encompasses Mainland China operations with export activities and international clinical trials, alongside potential subsidiary or affiliate structures to manage regional development and commercialization efforts. The description focuses on what the company does, its product categories, clinical-stage assets, technology platforms, and its ongoing strategic changes and international expansion to reach broader markets. Recent strategic changes include ongoing international phase III trials for BA6101 and BA1102 and plans for multiple BLAs filings over the next two years, reflecting a shift toward global regulatory approvals and commercialization beyond the Chinese market. The company emphasizes a pipeline-driven growth trajectory with emphasis on oncology antibodies, bispecifics, and ADCs, complemented by development in autoimmune, ophthalmic, and metabolic therapies to broaden its addressable markets. The latest major company changes involve expansion of international clinical programs, advancement of late-stage candidates into global trials, and potential future BLAs, signaling an intensified push toward international commercialization and regulatory approvals. The company continues to invest in platform technologies and pipeline expansion, maintaining a strategy of partnering, co-development, and potential acquisitions to strengthen its competitive position in the global biopharmaceutical landscape. This description consolidates Shandong Boan Biotechnology’s core business, product portfolio, platforms, and the latest strategic milestones as of the current reporting period.